Poor
Not Aligned
Patient Risk:
Moderate
Summary
Some core pharmacology/class and seizure indication statements are consistent with the provided label text, but multiple claims are unsupported or directly conflict with the label regarding indications and dosage forms, and several non-label assertions (price, availability, bioequivalence/equivalence studies) cannot be supported by the supplied prescribing information.
Category Scores
Accurate Statements
Clonazepam is a benzodiazepine medication.
Label includes benzodiazepine class safety warnings (e.g., opioid concomitant risks, abuse/misuse/addiction, dependence/withdrawal) and refers to clonazepam/“Klonopin” as a benzodiazepine.
Clonazepam works by enhancing the activity of GABA.
CLINICAL PHARMACOLOGY > Pharmacodynamics: mechanism is believed related to ability to enhance activity of gamma aminobutyric acid (GABA).
Unsupported Statements
Clonazepam is used to treat anxiety disorders.
Provided label text discusses panic disorder (DOSAGE AND ADMINISTRATION > Panic Disorder), but does not state a broader indication for 'anxiety disorders' in the supplied sections.
Clonazepam is used to treat insomnia.
No insomnia indication is stated in the supplied label text.
Aurobindo's clonazepam is a generic version of clonazepam.
The supplied label does not address Aurobindo branding, generic status, or product-specific equivalence.
Aurobindo's clonazepam is priced significantly lower than other brands.
The supplied prescribing information contains no pricing information.
A 30-day supply of Aurobindo's clonazepam 0.5 mg tablets costs around $10.
No pricing or cost data appear in the supplied label.
The same dosage from other brands can cost upwards of $50.
No pricing or comparative cost data appear in the supplied label.
Aurobindo's clonazepam has been shown to be just as effective as other brands in treating anxiety disorders.
No Aurobindo-specific comparative effectiveness or equivalence evidence is provided in the supplied label.
Aurobindo's clonazepam has been shown to be just as effective as other brands in treating seizure disorders.
No Aurobindo-specific comparative effectiveness or equivalence evidence is provided in the supplied label.
A study in the Journal of Clinical Psychopharmacology found Aurobindo's clonazepam is equivalent to the branded medication in efficacy.
The supplied label does not mention this journal or provide Aurobindo-specific efficacy equivalence evidence.
A study in the Journal of Clinical Psychopharmacology found Aurobindo's clonazepam is equivalent to the branded medication in tolerability.
The supplied label does not mention this journal or provide Aurobindo-specific tolerability equivalence evidence.
Aurobindo's clonazepam is widely available at most pharmacies.
The supplied label includes no information about distribution/availability.
Aurobindo's clonazepam can be found at online retailers.
The supplied label includes no information about online availability.
Aurobindo's clonazepam is available in capsules.
The supplied label states clonazepam is available as a tablet; no capsule formulation is described.
Aurobindo's clonazepam is available in oral solutions.
The supplied label states clonazepam is available as a tablet; no oral solution is described.
Some other brands may offer additional dosage forms such as injectable solutions.
The supplied label does not discuss other brands or additional dosage forms beyond the stated tablet formulation.
Some other brands may offer additional dosage forms such as suppositories.
The supplied label does not discuss other brands or additional dosage forms beyond the stated tablet formulation.
Contradictions
Low
AI Statement
Clonazepam is used to treat insomnia.
Label Reference
Provided label sections include labeled uses for panic disorder and seizure disorders, and contraindications/warnings; no insomnia indication is provided in the supplied prescribing information.
Low
AI Statement
Aurobindo's clonazepam is available in capsules.
Label Reference
DOSAGE AND ADMINISTRATION: “Clonazepam is available as a tablet.” (no capsule formulation described in supplied text)
Low
AI Statement
Aurobindo's clonazepam is available in oral solutions.
Label Reference
DOSAGE AND ADMINISTRATION: “Clonazepam is available as a tablet.” (no oral solution formulation described in supplied text)
Important Omissions
For any indication statements, the label text provided specifies panic disorder and specific seizure types/syndromes; it does not support generic wording like 'anxiety disorders' and does not include insomnia. If the intent was to convey labeled indications, the response should have referred specifically to panic disorder and the listed seizure disorders/conditions.
Importance:
Moderate
The label specifies dosing/administration instructions for tablets (administer with water by swallowing whole). The response did not address this administration instruction and instead asserted multiple unlabelled formulations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and potentially misleading indication claims (e.g., 'insomnia', 'anxiety disorders' broadly) and incorrect/unsupported formulation availability claims (capsules, oral solutions) could lead to mismatched use or expectations relative to the provided label. However, no direct dosing regimen, contraindication, or warning-carrying statements were made beyond class mechanism and general benzodiazepine characterization.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported by the supplied prescribing information, including non-label product/price/availability assertions and incorrect formulation claims; additionally, 'anxiety disorders' and 'insomnia' are not supported by the provided label sections.
Suggested Improvement
Limit indication statements to those explicitly present in the supplied label text (panic disorder; and specified seizure disorders/syndromes) and describe only the dosage form stated in the label (tablets administered with water by swallowing whole). Remove pricing, availability, and journal-equivalence assertions unless included in the prescribing information provided.